• Wondering if Penumbra at around US$325.33 is offering you real value or just a rich price tag? This article walks through what the latest numbers actually say about the stock.
• The share price shows a 1.4% decline over the last 7 days and a 1.1% decline over the last 30 days, while returns stand at 5.1% year to date and 9.9% over the past year.
• Recent coverage around Penumbra has focused on its position in the medical equipment space and how investors are weighing growth potential against risks. This context helps explain why the stock’s moves have been relatively measured rather than sharply one sided.
• Right now, Penumbra scores 0 out of 6 on Simply Wall St’s valuation checks, as shown in its valuation score. The next sections will walk through different valuation approaches and then finish with a framework that can help you interpret that score in a more practical way.

Penumbra scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Penumbra Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting them back to today using an appropriate rate. It is essentially asking what all those future cash flows are worth in today’s dollars.

For Penumbra, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow stands at about $199.9 million. Based on analyst inputs and further projections by Simply Wall St, forecast Free Cash Flow runs from $156.6 million in 2026 to $442.6 million in 2035, all in dollars. These ten year cash flows are discounted back to arrive at an estimated intrinsic value per share of about $180.37.

Compared with a recent share price around $325.33, this DCF outcome suggests the stock is around 80.4% above the model’s fair value estimate, so the shares screen as expensive on this cash flow basis.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Penumbra may be overvalued by 80.4%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Penumbra Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings, which makes it a straightforward cross check against the DCF view. A higher P/E can reflect strong growth expectations or lower perceived risk, while a lower P/E can point to weaker growth prospects or higher risk, so what counts as a “fair” P/E depends on these factors.

Penumbra currently trades on a P/E of about 72x. That sits well above the Medical Equipment industry average of about 23.6x and also above the peer average of about 29.7x. Simply Wall St’s Fair Ratio for Penumbra is 27.94x, which is its proprietary estimate of what a “normal” P/E might look like after accounting for the company’s earnings growth profile, profit margins, industry, market cap and risk factors.

This Fair Ratio can be more useful than a simple comparison with peers or the industry, because it adjusts for company specific characteristics rather than assuming all medical equipment stocks should trade on the same multiple. Set against the current P/E of 72x, the Fair Ratio of 27.94x points to Penumbra trading at a richer level than this framework would suggest.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Penumbra Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are a simple way for you to write the story behind your numbers, linking your view on Penumbra’s revenue, earnings and margins to a financial forecast and then to a Fair Value that you can compare with the current share price to decide whether you see the stock as attractive, fully priced or expensive.

On Simply Wall St’s Community page, Narratives are an accessible tool used by millions of investors. They update automatically when fresh information such as earnings results or trial data like STORM PE or STRIKE PE comes through, so your Fair Value and thesis stay aligned with what is happening at the company.

For Penumbra, one investor might build a more optimistic Narrative that lines up with a Fair Value around US$365.79 per share or even a bullish view closer to US$374.00. Another investor might choose a more cautious Narrative that matches a Fair Value closer to US$238.98 or even US$186.00. Seeing those side by side helps you decide which story best matches your expectations before acting on the stock.

For Penumbra, however, we will make it really easy for you with previews of two leading Penumbra Narratives.

Start by asking which of these feels closer to your view on how trials, product rollouts and margins might play out. Then use that as your reference point when you look at the current share price around US$325.33.

Fair Value: US$365.79 per share

Implied valuation gap vs current price: about 11.1% below this narrative fair value

Revenue growth used in this narrative: 13.24% a year

• Assumes trials such as STORM PE, new therapies such as RUBY XL and Thunderbolt, and a larger sales force support broad adoption across underpenetrated vascular treatment areas.
• Builds in continued global roll out with improving profit margins and a discount rate of 7.83% to bring future earnings and cash flows back to today.
• Anchors on analyst consensus numbers, including expected earnings of US$304.1 million by around 2029 and a future P/E that remains above the wider Medical Equipment industry.

Fair Value: US$238.98 per share

Implied valuation gap vs current price: about 36.1% above this narrative fair value

Revenue growth used in this narrative: 13.19% a year

• Assumes hospital protocols, budgets and reimbursement terms slow the uptake of pulmonary embolism and venous thromboembolism procedures that use Penumbra devices.
• Builds in pressure from competing thrombectomy and embolization platforms, higher ongoing SG&A from the enlarged sales footprint and product cycle risk around newer systems such as Thunderbolt and Lightning Flash 3.0.
• Uses a lower fair value of US$238.98 based on a 7.72% discount rate, a future P/E of 50.3x and earnings of US$244.7 million by 2028, which together point to the view that current market expectations may be too optimistic.

If you want to see how these bullish and bearish cases translate into detailed numbers, charts and full write ups, head over to the community narratives for Penumbra where both of these frameworks are laid out in full alongside other investor views. See what the community is saying about Penumbra

Do you think there's more to the story for Penumbra? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.